LAURA ROMUNDSTAD: Open Payments
NPI 1255757209 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,237 in 202 payments from 47 companies in 2025. Trend: 2023 $1,545 · 2024 $3,278 · 2025 $4,237
Food & beverage: $4,137Education: $100
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 23 | $546 |
| Novartis Pharmaceuticals Corporation | 19 | $397 |
| Merck Sharp & Dohme LLC | 10 | $246 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $235 |
| Genentech USA, Inc. | 11 | $204 |
| Celgene Corporation | 12 | $192 |
| BeOne Medicines USA, Inc. | 10 | $176 |
| CSL Behring | 5 | $150 |
| GlaxoSmithKline, LLC. | 8 | $142 |
| ABBVIE INC. | 7 | $126 |
Products named: KEYTRUDA, BRUKINSA, REBLOZYL, KISQALI, ERLEADA, Hizentra, Polivy, FRUZAQLA.
Industry payments across AL — which companies pay providers there.
